Skip to content
In English |
En español
Search
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -6 of 6
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/24/2003
 
First Published:
8/1/2001
1.
Phase III Study of Epratuzumab in Patients With Rituximab-Refractory Low-Grade Follicular B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0009041
IM-T-hLL2-07, UCLA-BB-IND-7124, NCI-G01-2004, NCT00022685
Last Modified:
3/1/1999
 
First Published:
1/1/1998
2.
Phase I/II Study of Immunotherapy with Humanized Monoclonal Antibody LL2 in Patients with Recurrent Non-Hodgkin's Lymphoma (Summary Last Modified 03/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
Not specified
Pharmaceutical / Industry
UNMC-289-97
IM-h-LL2-01, NCI-V97-1353
Last Modified:
9/10/2003
 
First Published:
8/1/2002
3.
Phase II Randomized Study of Epratuzumab in Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0201056
AMGEN-AMG-412-159, NCI-G02-2094, NCT00042913
Last Modified:
2/27/2003
 
First Published:
1/26/2003
4.
Phase II Study of Epratuzumab and Rituximab in Patients With Refractory or Recurrent Low-Grade CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0109058
AMGEN-20010138, NCT00054379
Last Modified:
8/16/2007
 
First Published:
3/3/2006
5.
Phase II Study of Epratuzumab and Rituximab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (CHOP) in Patients With Previously Untreated Stage II, III, or IV Diffuse Large B-Cell Lymphoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Closed
18 and over
NCI
NCCTG-N0489
N0489, NCT00301821
Last Modified:
6/1/1995
6.
Phase I Pilot Study of 131I-Labeled MOAB LL2 for B-Cell non-Hodgkin's Lymphoma (Summary Last Modified 06/95)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
over 18
UCHSC-91264
NCI-V91-0216
Select All on One Page
NCI Home
|
Text-Only Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute